

Resource Summary Report

Generated by [NIF](#) on Aug 6, 2026

TC-1 [Mouse lung]

RRID:CVCL_4699

Type: Cell Line

Proper Citation

CLS Cat# 305388, RRID:CVCL_4699

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_4699

Proper Citation: CLS Cat# 305388, RRID:CVCL_4699

Description: Cell line TC-1 [Mouse lung] is a Transformed cell line with a species of origin *Mus musculus* (Mouse)

Sex: Sex unspecified

Defining Citation: [PMID:8548765](#), [PMID:12559790](#), [PMID:31638243](#)

Category: Transformed cell line

Organism: *Mus musculus* (Mouse)

Name: TC-1 [Mouse lung]

Synonyms: TC-1[JHU-1], Tissue Culture-1

Cross References: BTO:BTO_0004795, CLO:CLO_0009279, ATCC:CRL-2785, ATCC:JHU-1, CLS:305388, NCBI_Iran:C569, Wikidata:Q54971787

ID: CVCL_4699

Vendor: CLS

Catalog Number: 305388

Record Creation Time: 20260408T074623+0000

Record Last Update: 20260802T010619+0000

Ratings and Alerts

No rating or validation information has been found for TC-1 [Mouse lung].

Warning: Discontinued: ATCC; JHU-1

Warning: Discontinued: ATCC; CRL-2785

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 411 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Liu J, et al. (2026) Extracellular GPX4 impairs antitumor immunity via dendritic ZP3 receptors. *Cell*.

Johari SD, et al. (2025) Inhibition of Aspartate γ -Hydroxylase Enhances Anti-Tumor Immunity. *ImmunoTargets and therapy*, 14, 697.

Jansons J, et al. (2025) New mouse model based on adenocarcinoma 4T1 cells expressing HPV16 E6 and E7 applied to assess the efficacy of therapeutic and prophylactic E6/E7-based HPV16 vaccines. *Infectious agents and cancer*, 20(1), 51.

Cabrera-Licon A, et al. (2025) Exploring the Anticancer Activity of Artocarpus heterophyllus Leaves: Selective Effects on Triple-Negative Breast Cancer and HPV16-Positive Tumorigenic Cells. *Life (Basel, Switzerland)*, 15(7).

Groeneveldt C, et al. (2024) Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell-Based Immunotherapies. *Cancer immunology research*, 12(3), 334.

Kanwal M, et al. (2024) Aspartate γ -hydroxylase Regulates Expression of Ly6 Genes. *Journal of Cancer*, 15(5), 1138.

Kim HY, et al. (2024) Specific targeting of cancer vaccines to antigen-presenting cells via an endogenous TLR2/6 ligand derived from cysteinyl-tRNA synthetase 1. *Molecular therapy : the journal of the American Society of Gene Therapy*, 32(10), 3597.

Becker W, et al. (2024) Second-generation checkpoint inhibitors and Treg depletion synergize with a mouse cancer vaccine in accordance with tumor microenvironment characterization. *Journal for immunotherapy of cancer*, 12(7).

Montégut L, et al. (2024) Acyl-coenzyme a binding protein (ACBP) - a risk factor for cancer diagnosis and an inhibitor of immunosurveillance. *Molecular cancer*, 23(1), 187.

van Elsas MJ, et al. (2023) Invasive margin tissue-resident macrophages of high CD163 expression impede responses to T cell-based immunotherapy. *Journal for immunotherapy of cancer*, 11(3).

Mikyskova R, et al. (2023) STAT3 inhibitor Stattic and its analogues inhibit STAT3 phosphorylation and modulate cytokine secretion in senescent tumour cells. *Molecular medicine reports*, 27(4).

Raman SNT, et al. (2023) Bivalent vaccines effectively protect mice against influenza A and respiratory syncytial viruses. *Emerging microbes & infections*, 12(1), 2192821.

Kagabu M, et al. (2023) Treatment of HPV-Related Uterine Cervical Cancer with a Third-Generation Oncolytic Herpes Simplex Virus in Combination with an Immune Checkpoint Inhibitor. *International journal of molecular sciences*, 24(3).

Jianyi D, et al. (2023) Myeloid-derived suppressor cells cross-talk with B10 cells by BAFF/BAFF-R pathway to promote immunosuppression in cervical cancer. *Cancer immunology, immunotherapy : CII*, 72(1), 73.

Ban W, et al. (2023) Engineered bacterial outer membrane vesicles encapsulating oncolytic adenoviruses enhance the efficacy of cancer virotherapy by augmenting tumor cell autophagy. *Nature communications*, 14(1), 2933.

Firdaus FZ, et al. (2023) Liposomal Formulations of a Polyleucine-Antigen Conjugate as Therapeutic Vaccines against Cervical Cancer. *Pharmaceutics*, 15(2).

Pandit M, et al. (2023) Methionine consumption by cancer cells drives a progressive upregulation of PD-1 expression in CD4 T cells. *Nature communications*, 14(1), 2593.

Kansal V, et al. (2023) Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models. *Journal for immunotherapy of cancer*, 11(1).

Li D, et al. (2023) A "trained immunity" inducer-adjuvanted nanovaccine reverses the growth of established tumors in mice. *Journal of nanobiotechnology*, 21(1), 74.

Skelved N, et al. (2023) Bispecific T cell-engager targeting oncofetal chondroitin sulfate induces complete tumor regression and protective immune memory in mice. *Journal of experimental & clinical cancer research : CR*, 42(1), 106.